|
A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Avandia™ XR and AVANDIA™ (4mg BD) in Patients with Type 2 Diabetes |
rosiglitazone |
49653/183 |
|
Diabetes Mellitus, Type 2 |
Phase 3 |
|
|
|
|
A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. |
February 2015 |